- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00623662
Preoperative Glucose Infusion: a Novel Strategy to Improve Liver Function After Liver Resection
Metabolic Preconditioning Using Intravenous Dextrose: a Novel Strategy to Improve Hepatic Function After Liver Resection
The goal of the study is to determine whether intravenous glucose administration before liver resection preserves hepatic glycogen resulting in improved hepatic metabolic function after the operation.
We further investigate whether the benefit of avoiding preoperative fasting is more pronounced in patients undergoing more extensive liver resection.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background. With a reported incidence of up to 70%, liver failure is the most frequent complication necessitating intensive care and prolonging hospital stay. Animal studies suggest that the glycogen content of the liver is a key regulator of liver function and that glycogen depletion, a mandatory consequence of preoperative fasting, is associated with poor clinical outcome.
The results of a pilot study demonstrate that metabolic preconditioning, i.e. the avoidance of preoperative fasting by intravenous administration of dextrose preserves hepatic glycogen and prevents hepatic dysfunction after liver resection. Liver function in this protocol was assessed by a score originally proposed by Schindl including serum concentrations of total bilirubin and lactate, prothrombin time and degree of encephalopathy. Due to alterations induced by anesthesia and surgery, e.g. blood loss necessitating transfusion, hypothermia, inflammatory responses and use of drugs with impact on hepatobiliary metabolism, liver function scores do not necessarily reflect functional integrity and metabolic capacity of the liver. In contrast, measuring the production of proteins that are exclusively synthetized by hepatocytes such as albumin allows a more specific and quantitative assessment of hepatic performance under perioperative conditions.
Hypothesis. We propose a randomized double-blinded study to test the hypothesis that, in patients scheduled for resection of liver cancer, metabolic preconditioning with intravenous dextrose preserves hepatic glycogen resulting in improved hepatic metabolic function postoperatively. We further hypothesize that the benefit of avoiding preoperative fasting is more pronounced in patients undergoing more extensive liver resection. Hepatic synthetic capacity will be assessed by measuring albumin synthesis using a stable isotope tracer technique.
Research plan. In order to test the validity of our assumptions, we will perform studies in patients scheduled for minor (study I; one or two liver segments, n=30) or major (study II; three or more liver segments, n=20) liver resection. In a double blinded fashion patients will be randomly assigned to receive either intravenous dextrose at 2 mg/kg/min or saline from 15:00 on the day before the operation until surgical skin incision. Metabolic processes at the organ level (liver, muscle), i.e. fractional synthesis rates of albumin, hepatic acute phase proteins (transthyretin (=prealbumin), fibrinogen, total plasma proteins) and muscle protein will be determined one day before and one day after the operation using primed-continuous infusions of L-[2H5]phenylalanine. Stable isotopes (L-[1-13C]leucine, [6,6-2H2]glucose) will be applied to assess dynamic changes in whole body protein and glucose metabolism before and after surgery, i.e. protein breakdown, amino acid oxidation, protein synthesis, glucose production and glucose uptake.
Significance. The demonstration that the preconditioning with dextrose preserves metabolic performance of the liver would have important implications for the clinical management of surgical patients with liver cancer. If preoperative dextrose administration attenuates hepatic dysfunction after liver resection, it will provide these patients with a readily available, safe and inexpensive therapy.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H3A 1A1
- Recruiting
- Royal Victoria Hospital, McGill University Health Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- American Society of Anesthesiologists class ≤3
- liver resection (one or more liver segments) for primary or secondary malignancy
- ability to give informed consent
Exclusion Criteria:
- signs of severe malnutrition or obesity: body mass index (BMI) <20 or >30 kg.m-2, more than 10% involuntary body weight loss over the preceding six months, serum albumin <35 g.L-1
- chronic viral liver disease
- diabetes mellitus
- significant cardiorespiratory, renal and neurological disease
- musculoskeletal or neuromuscular disease
- severe anemia (hemoglobin <10 g.dL-1)
- history of severe sciatica or back surgery or other conditions which contraindicate the use of an epidural catheter
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: 1
Glucose infusion.
|
Glucose infusion from 15:00 on the day before the operation until beginning of surgery.
|
|
Placebo Comparator: 2
Normal saline infusion.
|
Normal saline infusion from 15:00 on the day before surgery until beginning of the operation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Rate of albumin synthesis
Time Frame: One day before and one day after surgery
|
One day before and one day after surgery
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Transthyretin synthesis, fibrinogen synthesis, whole body glucose and protein kinetics
Time Frame: One day before and one day after surgery
|
One day before and one day after surgery
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ralph Lattermann, MD PhD, Department of Anaesthesia, McGill University Health Centre
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GEN-07-075
- CIHR 183635
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Failure
-
Institute of Liver and Biliary Sciences, IndiaCompletedAcute Liver FailureIndia
-
Beijing Continent Pharmaceutical Co, Ltd.RecruitingAcute-On-Chronic Liver Failure | Acute Liver FailureChina
-
Tianjin Weikai Bioeng., Ltd.Tianjin Nankai HospitalUnknownLiver Failure, Acute on ChronicChina
-
Institute of Liver and Biliary Sciences, IndiaCompletedAcute Liver Failure | Acute on Chronic Liver FailureIndia
-
GenfitCompletedAcute-on-Chronic Liver FailureUnited States
-
HLB Cell Co., Ltd.UnknownAcute-On-Chronic Liver Failure | Acute Liver FailureKorea, Republic of
-
Li-Ying SunNot yet recruitingAcute Liver Failure
-
Nanfang Hospital of Southern Medical UniversityCompletedLiver Injury | Liver Failure, Acute on Chronic
-
Institute of Liver and Biliary Sciences, IndiaIndian Council of Medical ResearchNot yet recruiting
-
Institute of Liver and Biliary Sciences, IndiaIndian Council of Medical ResearchNot yet recruiting
Clinical Trials on Preoperative glucose infusion
-
Peking University People's HospitalUnknownPulmonary Nodule, Solitary | Pulmonary Nodule, MultipleChina
-
University of Texas Southwestern Medical CenterCompletedSarcoma | Neuroblastoma | Pediatric CancerUnited States
-
University of OxfordWellcome Trust; St George's, University of LondonCompleted
-
University of AarhusCompleted
-
University College, LondonCancer Research UKCompleted
-
Catholic University of the Sacred HeartSteno Diabetes Center CopenhagenCompletedType 2 Diabetes MellitusItaly
-
Aretaieion University HospitalCompletedCardiac Surgery | Cardiac Disease | Cardiac Failure | Inotropes | Ejection FractionGreece
-
University Hospital, Gentofte, CopenhagenCompletedInsulin Resistance | Type 2 Diabetes | Incretin EffectDenmark
-
University Hospital, Gentofte, CopenhagenCompletedType 2 Diabetes MellitusDenmark
-
Suzhou Municipal Hospital of Anhui ProvinceCompletedCerebrovascular Disorders | Intradialytic Hypotension | Cardiovascular Diseases (CVD) | Dialysis Adequacy | Uremia; Chronic | Ultrafiltration IntoleranceChina